Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2020 Publisher: Recordati Pharmaceuticals Limited, Origin, Western Road, Bracknell, RG12 1US, United Kingdom
Urispas 200 mg Film-coated Tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet. White, film-coated tablets embossed with ‘F 200’. |
Each tablet contains as active ingredient: flavoxate hydrochloride 200 mg.
Excipient with known effect: Each tablet contains 64 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Flavoxate |
Flavoxate is an antispasmodic selective to the urinary tract. Flavoxate has been shown to have a direct antispasmodic action on smooth muscle fibres. |
| List of Excipients |
|---|
|
Tablet Core: Lactose monohydrate Tablet Coating: Hypromellose |
PVC/aluminium blister strips in pack sizes of 84, 90, 100 and 250 tablets. Not all pack sizes may be marketed.
Recordati Pharmaceuticals Limited, Origin, Western Road, Bracknell, RG12 1US, United Kingdom
PL 25046/0006
Date of first authorisation: 30 May 1997
Date of latest renewal: 14 August, 2007
| Drug | Countries | |
|---|---|---|
| URISPAS | France, Hong Kong, Ireland, Lithuania, Netherlands, Singapore, Turkey, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
